Interleukin-1β-induced interleukin-6 production in A549 cells is mediated by both phosphatidylinositol 3-kinase and interleukin-1 receptor-associated kinase-4

被引:23
|
作者
Eda, Hiroyuki [1 ]
Burnette, Barry L. [1 ]
Shimada, Hideaki [1 ]
Hope, Heidi R. [1 ]
Monahan, Joseph B. [1 ]
机构
[1] St Louis Labs Pfizer Inc, Discovery Biol, Global Res & Dev, Chesterfield, MO 63017 USA
关键词
interleukin-6 (IL-6); interleukin-1 receptor associated kinase-4 (IRAK4); phosphatidylinositol 3-kinase (PI3K); rheumatoid arthritis synovial fibroblast (RASF); signal transduction; small interfering RNA (siRNA); NF-KAPPA-B; ACTIVATION; PHOSPHORYLATION; REQUIRES; IRAK;
D O I
10.1042/CBI20100247
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The aim of this study is to investigate whether PI3K (phosphatidylinositol-3-kinase) is involved in IL-1 beta(interleukin-1 beta)-induced IL-6 production in A549 (human lung adenocarcinoma epithelial cell) and human RASF (rheumatoid arthritis synovial fibroblast). PI3K inhibitor, LY294002 significantly reduced IL-1 beta-induced IL-6 production in A549 cells but not in RASF, indicating that IL-1 beta-induced IL-6 production was partially mediated by PI3Kin A549 cells but not in RASF. siRNA (small interfering RNA) of IRAK4 (IL-1 receptor-associated kinase 4) treatment decreased IRAK4 mRNA level by up to 90% in A549 cells. In this condition, IL-1 beta-induced increase of IL-6 mRNA and protein level was decreased by up to 93% and 70%, respectively. Furthermore, the combination of IRAK4 siRNA and LY294002 treatment decreased protein induction level of IL-6 in A549 cells compared with that of IRAK4 siRNA or LY294002 alone. These results indicate that IL-1 beta-induced IL-6 production in A549 cells is mediated by both PI3K and IRAK4 and suggest that involvement of PI3K in the IL-1-induced IL-6 production is cell type specific.
引用
收藏
页码:355 / 358
页数:4
相关论文
共 50 条
  • [1] A case of chilblains associated with interleukin-1 receptor-associated kinase-4 deficiency
    Gurung, P.
    Lee, A.
    Armon, K.
    Millington, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 : 154 - 155
  • [2] Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4
    Powers, JP
    Li, SY
    Jaen, JC
    Liu, JQ
    Walker, NPC
    Wang, ZL
    Wesche, H
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (11) : 2842 - 2845
  • [3] The Role of interleukin-1 receptor-associated kinase 4 in drug addiction
    Wu, Ruyan
    Liu, Jian-Feng
    Vu, Jimmy
    Johnson, Bernard
    Li, Jun-Xu
    FASEB JOURNAL, 2019, 33
  • [4] The Role of Interleukin-1 Receptor-Associated Kinase 4 in Drug Addiction
    李俊旭
    神经药理学报, 2019, 9(Z1) (Z1) : 19 - 20
  • [5] The Role of Interleukin-1 Receptor-Associated Kinase 4 in Opioid Addiction
    Wu, Ruyan
    Liu, Jianfeng
    Vu, Jimmy
    Johnson, Bernard
    Li, Jun-Xu
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 501 - 501
  • [6] Interleukin-1 Receptor-Associated Kinase 4 Deficiency in a Greek Teenager
    Karananou, Panagiota
    Alataki, Anastasia
    Papadopoulou-Alataki, Efimia
    CASE REPORTS IN IMMUNOLOGY, 2020, 2020
  • [7] Lipopolysaccharide-induced gene expression of interleukin-1 receptor-associated kinase 4 and interleukin-1β in roughskin sculpin (Trachidermus fasciatus)
    Liu, Yingying
    Yu, Shanshan
    Chai, Yingmei
    Zhang, Qiuxia
    Yang, Hui
    Zhu, Qian
    FISH & SHELLFISH IMMUNOLOGY, 2012, 33 (04) : 690 - 698
  • [8] Interleukin-1 receptor-associated kinase-1: More evidence
    Moretti, Eugene W.
    CRITICAL CARE MEDICINE, 2010, 38 (12) : 2410 - 2411
  • [9] Chilblains accompanying interleukin-1 receptor-associated kinase (IRAK)-4 deficiency
    Gurung, P.
    Lee, A. S. W.
    Armon, K.
    Millington, G. W. M.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2018, 43 (05) : 596 - 597
  • [10] Ecthyma Gangrenosum in an Infant with Interleukin-1 Receptor-Associated Kinase 4 Deficiency
    Kanno, Koji
    Cho, Yoshiaki
    Fujii, Shuichi
    Ami, Yuki
    Nishizeki, Osamu
    Sonoda, Motoshi
    Ishimura, Masataka
    Fujiwara, Naoki
    JOURNAL OF PEDIATRICS, 2021, 239 : 241 - 242